Development of decision tree models for substrates, inhibitors, and inducers of P-glycoprotein

Current Drug Metabolism

Volumn 10, Issue 4, 2009, Pages 339-346

  Hammann, Felix ^a   Gutmann, Heike ^a   Jecklin, Ursula ^a   Maunz, Andreas ^b   Helma, Christoph ^b   Drewe, Juergen ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Calcein AM assay; Decision trees; MDR1; Multidrug resistance; P glycoprotein; QSAR

Indexed keywords

CALCEIN; GLYCOPROTEIN P;

ACCURACY; ARTIFICIAL NEURAL NETWORK; BIOASSAY; CLASSIFICATION ALGORITHM; COMPUTER MODEL; DECISION TREE; KAPPA STATISTICS; MACHINE LEARNING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TISSUE DISTRIBUTION;

COMPUTER SIMULATION; DECISION TREES; ENZYME INDUCTION; FLUORESCEINS; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 68349131384     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009788499021     Document Type: Review

References (70)

1. Huls, M.; Russel, F. G.; Masereeuw, R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J. Pharmacol. Exp. Ther., 2009, 328(1), 3-9.
2. Cordon-Cardo, C.; O'Brien, J. P.; Boccia, J.; Casals, D.; Bertino, J. R.; Melamed, M. R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem., 1990, 38(9), 1277-1287.
3. Petraccia, L.; Onori, P.; Sferra, R.; Lucchetta, M. C.; Liberati, G.; Grassi, M.; Gaudio, E. MDR (multidrug resistance) in hepatocarcinoma clinical-therapeutic implications. Clin. Ter., 2003, 154(5), 325-335.
4. Zhou, S. F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 2008, 38(7-8), 802-832.
5. Mizutani, T.; Masuda, M.; Nakai, E.; Furumiya, K.; Togawa, H.; Nakamura, Y.; Kawai, Y.; Nakahira, K.; Shinkai, S.; Takahashi, K. Genuine functions of P-glycoprotein (ABCB1). Curr. Drug Metab., 2008, 9(2), 167-174.
6. Gerlach, J. H.; Endicott, J. A.; Juranka, P. F.; Henderson, G.; Sarangi, F.; Deuchars, K. L.; Ling, V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature, 1986, 324(6096), 485-489.
7. Hughes, J. R. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol. Res., 2008, 30(9), 920-925.
8. Dhananjay, P.; Mitra, A. K. MDR- and CYP3A4-mediated drug-drug interactions. J. Neuroimmune Pharmacol., 2006, 1(3), 323-339.
9. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther., 2008, 325(2), 349-356.
10. Yacyshyn, B.; Maksymowych, W.; Bowen-Yacyshyn, M. B. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Hum. Immunol., 1999, 60(8), 677-687.
11. Fiocchi, C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology, 1998, 115(1), 182-205.
12. Rescigno, M. The pathogenic role of intestinal flora in IBD and colon cancer. Curr. Drug Targets, 2008, 9(5), 395-403.
13. Henckaerts, L.; Figueroa, C.; Vermeire, S.; Sans, M. The role of genetics in inflammatory bowel disease. Curr. Drug Targets, 2008, 9(5), 361-368.
14. Annese, V.; Valvano, M. R.; Palmieri, O.; Latiano, A.; Bossa, F.; Andriulli, A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J. Gastroenterol., 2006, 12(23), 3636-3644.
15. Gutmann, H.; Hruz, P.; Zimmermann, C.; Straumann, A.; Terracciano, L.; Hammann, F.; Lehmann, F.; Beglinger, C.; Drewe, J. Breast cancer resistance protein and P-glycoprotein expression in patients with newly diagnosed and therapy-refractory ulcerative colitis compared with healthy controls. Digestion, 2008, 78(2-3), 154-162.
16. Englund, G.; Jacobson, A.; Rorsman, F.; Artursson, P.; Kindmark, A.; Ronnblom, A. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm. Bowel Dis., 2007, 13(3), 291-297.
17. Henckaerts, L.; Figueroa, C.; Vermeire, S.; Sans, M. The role of genetics in inflammatory bowel disease. Curr. Drug Targets, 2008, 9(5), 361-368.
18. Buchman, A. L.; Paine, M. F.; Wallin, A.; Ludington, S. S. A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig. Dis. Sci., 2005, 50(12), 2312-2315.
19. Sambuelli, A. M.; Negreira, S. M.; Gil, A. H.; Huernos, S. P.; Goncalves, S.; Toro, M. A.; Kogan, Z.; Cabanne, A.; Camarero, S.; Bai, J. C.; Lazarowski, A. J. Multidrug resistance gene (MDR-1) expression in the colonic mucosa of patients with refractory ulcerative colitis. Acta Gastroenterol. Latinoam., 2006, 36(1), 23-32.
20. Chambers, S. K.; Hait, W. N.; Kacinski, B. M.; Keyes, S. R.; Handschumacher, R. E. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. Cancer Res., 1989, 49(22), 6275-6279.
21. Coley, H. M.; Twentyman, P. R.; Workman, P. Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochem. Pharmacol., 1989, 38(24), 4467-4475.
22. Hait, W. N.; Gesmonde, J. F.; Murren, J. R.; Yang, J. M.; Chen, H. X.; Reiss, M. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem. Pharmacol., 1993, 45(2), 401-406.
23. Hait, N. C.; Sarkar, S.; Le Stunff, H.; Mikami, A.; Maceyka, M.; Milstien, S.; Spiegel, S. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J. Biol. Chem., 2005, 280(33), 29462-29469.
24. Tiberghien, F.; Loor, F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs, 1996, 7(5), 568-578.
25. Sun, H.; Chow, E. C.; Liu, S.; Du, Y.; Pang, K. S. The Caco-2 cell monolayer: usefulness and limitations. Expert Opin. Drug Metab. Toxicol., 2008, 4(4), 395-411.
26. Stouch, T. R.; Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug Deliv. Rev., 2002, 54(3), 315-328.
27. Elsinga, P. H.; Hendrikse, N. H.; Bart, J.; Vaalburg, W.; van Waarde, A. PET Studies on P-glycoprotein function in the bloodbrain barrier: how it affects uptake and binding of drugs within the CNS. Curr. Pharm. Des., 2004, 10(13), 1493-1503.
28. Hau, P.; Fabel, K.; Baumgart, U.; Rummele, P.; Grauer, O.; Bock, A.; Dietmaier, C.; Dietmaier, W.; Dietrich, J.; Dudel, C.; Hubner, F.; Jauch, T.; Drechsel, E.; Kleiter, I.; Wismeth, C.; Zellner, A.; Brawanski, A.; Steinbrecher, A.; Marienhagen, J.; Bogdahn, U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 2004, 100(6), 1199-1207.
29. Huang, J.; Ma, G.; Muhammad, I.; Cheng, Y. Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm. J. Chem. Inf. Model., 2007, 47(4), 1638-1647.
30. Seelig, A.; Landwojtowicz, E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci., 2000, 12(1), 31-40.
31. Crivori, P.; Reinach, B.; Pezzetta, D.; Poggesi, I. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol. Pharm., 2006, 3(1), 33-44.
32. Muller, H.; Pajeva, I. K.; Globisch, C.; Wiese, M. Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg. Med. Chem., 2008, 16(5), 2448-2462.
33. Johnson, M. A.; Maggiora, G. M., Concepts and Applications of Molecular Similarity. 1st ed.; Wiley: New York, 1990.
34. Lahana, R. How many leads from HTS? Drug Discov Today, 1999, 4(10), 447-448.
35. ATP-binding cassette sub-family B member 1 [Homo sapiens], Calcein AM assay. Natl Center Biotechnol Inf., Bethesda, MD, USA, PubChem: 2006; http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=377
36. Mayo, S. L.; Olafson, B. D.; Goddard, W. A. DREIDING: A generic force field for molecular simulations. J. Phys. Chem., 1990, 94, 8897-8909.
37. Randic, M. Characterization of molecular branching. J. Am. Chem. Soc., 1975, 97(23), 6609-6615.
38. Platt, J. R. Influence of neighbor bonds on additive bond properties in paraffins. J. Chem. Phys., 1947, 15(6), 419-420.
39. Wiener, H. Structural Determination of Paraffin Boiling Points. J. Am. Chem. Soc., 1947, 69(1), 17-20.
40. Kier, L. B.; Hall, L. H. General definition of valence delta-values for molecular connectivity. J. Pharm. Sci., 1983, 72(10), 1170-1173.
41. Kier, L. B.; Hall, L. H. Molecular Structure Description: The Electrotopological State. 1st ed.; Academic Press: San Diego, CA, 1999.
42. Khadikar, P. V.; Deshpande, N. V.; Kale, P. P.; Dobrynin, A.; Gutman, I.; Domotor, G. The Szeged Index and an Analogy with the Wiener Index. J. Chem. Inf. Comput. Sci., 1995, 35(3), 547-550.
43. Willett, P. Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today, 2006, 11(23-24), 1046-1053.
44. Willett, P.; Barnard, J. M.; Downs, G. M. Chemical Similarity Searching. J. Chem. Inf. Comput. Sci., 1998, 38, 983-996.
45. Hollo, Z.; Homolya, L.; Hegedus, T.; Muller, M.; Szakacs, G.; Jakab, K.; Antal, F.; Sarkadi, B. Parallel functional and immunological detection of human multidrug resistance proteins, P-glycoprotein and MRP1. Anticancer Res., 1998, 18(4C), 2981-2987.
46. Karaszi, E.; Jakab, K.; Homolya, L.; Szakacs, G.; Hollo, Z.; Telek, B.; Kiss, A.; Rejto, L.; Nahajevszky, S.; Sarkadi, B.; Kappelmayer, J. Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. Br. J. Haematol., 2001, 112(2), 308-314.
47. Psychoactive Drug Screening Program, MDR-1. Natl Inst Mental Health, Bethesda, MD, USA, Psychoactive Drug Screening Program: 2006; http://pdsp.med.unc.edu
48. Quinlan, J. R. Induction of decision trees. Mach. Learn., 1986, 1(1), 81-106.
49. Quinlan, J. R. C4.5 Programs for Machine Learning. 1st ed.; Morgan Kaufmann: San Francisco, 1993.
50. Breiman, L. Classification and Regression Trees. 1st ed.; Chapman & Hall/CRC: Boca Raton, 1984.
51. Sonquist, J. A.; Morgan, J. N., The Detection of Interaction Effects. 1st ed.; Survey Research Center, Institute for Social Research, University of Michigan: Ann Arbor, 1964, p. 296.
52. Gini, C. Variabilità e mutabilità. Memorie di Metodologica Statistica, 1912.
53. Kohavi, R. In A study of cross-validation and bootstrap for accuracy estimation and model selection, Int Joint Conf Artif Intell Montreal, Quebec, Canada, 1995; Digit Lib India, http://dli.iiit.ac.in; pp 1137-1143.
54. Cohen, J. A coefficient of agreement for nominal scales. Educ. Psychol. Meas., 1960, 20(1), 37-46.
55. Landis, J. R.; Koch, G. G. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics, 1977, 33(2), 363-374.
56. Landis, J. R.; Koch, G. G. The measurement of observer agreement for categorical data. Biometrics, 1977, 33(1), 159-174.
57. Steinbeck, C.; Han, Y.; Kuhn, S.; Horlacher, O.; Luttmann, E.; Willighagen, E. The Chemistry Development Kit (CDK): an open-source Java library for Chemo- and Bioinformatics. J. Chem. Inf. Comput. Sci., 2003, 43(2), 493-500.
58. Qian, X. D.; Beck, W. T. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res., 1990, 50(4), 1132-1137.
59. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos., 2005, 33(1), 165-174.
60. de Cerqueira Lima, P.; Golbraikh, A.; Oloff, S.; Xiao, Y.; Tropsha, A. Combinatorial QSAR modeling of P-glycoprotein substrates. J. Chem. Inf. Model., 2006, 46(3), 1245-1254.
61. Chang, C.; Ekins, S.; Bahadduri, P.; Swaan, P. W. Pharmacophore-based discovery of ligands for drug transporters. Adv. Drug Deliv. Rev., 2006, 58(12-13), 1431-1450.
62. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther., 2001, 299(2), 620-628.
63. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther., 2003, 28(3), 203-228.
64. Didziapetris, R.; Japertas, P.; Avdeef, A.; Petrauskas, A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target., 2003, 11(7), 391-406.
65. Zhou, S. F.; Lai, X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr. Drug Metab., 2008, 9(5), 394-409.
66. Carson, S. W.; Ousmanou, A. D.; Hoyler, S. L. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology. Psychopharmacol. Bull., 2002, 36(1), 67-81.
67. Zastre, J. A.; Chan, G. N.; Ronaldson, P. T.; Ramaswamy, M.; Couraud, P. O.; Romero, I. A.; Weksler, B.; Bendayan, M.; Bendayan, R. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res., 2008, 87(4), 1023-1036.
68. Breiman, L. Bagging Predictors. Mach. Learn., 1996, 24(2), 123-140.
69. Huang, J.; Ma, G.; Muhammad, I.; Cheng, Y. Identifying P-glycoprotein substrates using a support vector machine optimized by a particle swarm. J. Chem. Inf. Model., 2007, 47(4), 1638-1647.
70. Wang, Y. H.; Li, Y.; Yang, S. L.; Yang, L. Classification of substrates and inhibitors of P-glycoprotein using unsupervised machine learning approach. J. Chem. Inf. Model., 2005, 45(3), 750-757.